Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $18.00 Consensus Target Price from Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been given a consensus rating of “Hold” by the twenty-one analysts that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $18.00.

NTLA has been the subject of several research analyst reports. Wedbush lowered their price objective on Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Robert W. Baird set a $7.00 price objective on Intellia Therapeutics in a report on Tuesday, January 27th. Barclays decreased their price objective on shares of Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday, November 7th. Bank of America lowered their target price on Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Finally, Wolfe Research reiterated a “peer perform” rating on shares of Intellia Therapeutics in a research note on Wednesday, November 12th.

Insider Activity

In other news, CEO John M. Leonard sold 34,146 shares of Intellia Therapeutics stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the transaction, the chief executive officer directly owned 1,013,339 shares in the company, valued at approximately $9,332,852.19. This trade represents a 3.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP James Basta sold 10,397 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the transaction, the executive vice president owned 101,528 shares in the company, valued at approximately $935,072.88. This trade represents a 9.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 53,051 shares of company stock worth $488,600 in the last three months. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors have recently modified their holdings of the business. Comerica Bank grew its stake in Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after acquiring an additional 901 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Intellia Therapeutics in the 2nd quarter valued at about $26,000. Blue Bell Private Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics during the third quarter valued at about $30,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Intellia Therapeutics in the 3rd quarter worth approximately $30,000. Finally, Whipplewood Advisors LLC increased its holdings in Intellia Therapeutics by 114,900.0% in the 2nd quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock valued at $32,000 after purchasing an additional 3,447 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $12.00 on Monday. The stock’s fifty day moving average price is $11.04 and its two-hundred day moving average price is $12.94. Intellia Therapeutics has a one year low of $5.90 and a one year high of $28.25. The firm has a market cap of $1.39 billion, a PE ratio of -2.81 and a beta of 2.10.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.